Latest Headlines

Latest Headlines

FDA review heralds first-in-class status for Gilead's hep C drug sofosbuvir

Gilead's sofosbuvir appears headed for a quick if not early approval from the FDA, which would set it firmly on a path to a megablockbuster market, with a wide variety of analysts estimating peak annual sales at $5 billion-plus.

Boehringer advances hep C contender into pivotal trial

Boehringer Ingelheim has begun enrolling patients in a pivotal late-stage hepatitis C study. The therapy combines faldaprevir (BI 201335), a protease inhibitor administered once daily, and BI 207127, a non-nucleoside polymerase inhibitor taken twice daily, plus ribavirin.

Abbott's interferon-free hep C combo wows in PhIIb test

Abbott Laboratories made a late entry into the red-hot race to develop an interferon-free approach to hepatitis C. But after playing catch-up with the likes of Gilead, it's now aiming for the inside track.

Abbott wows the crowd with promising Phase II hep C data

You can count Abbott as a key player in the hot hepatitis C drug development race.